Clinical trial
Open-Label Trial of Atomoxetine to Evaluate Academic Outcome in Children Ages…
NCT00191880 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00191880 |
|---|---|
| Title | Open-Label Trial of Atomoxetine to Evaluate Academic Outcome in Children Ages 8-11 Years With Attention Deficit/Hyperactivity Disorder |
| Official title | A Phase IIIb Open-Label Trial of Atomoxetine Hydrochloride to Evaluate Academic Outcome in Children Ages 8 to 11 Years With Attention-Deficit/Hyperactivity Disorder |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Attention Deficit Hyperactivity Disorder |
| Intervention type | Drug |
| Interventions | atomoxetine |
| Enrollment | 100 |
| Start date | May 1, 2004 |
| Completion | Jun 1, 2006 |
| First posted | Sep 19, 2005 |
| Last update posted | Aug 29, 2006 |
| Countries | Canada |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: